Equity Research Services-Health Services

Should You Buy Agape ATP Corporation Stock in 2026?

By CirclFi Research Team · · 11/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Agape ATP Corporation (ATPC) scores 4.6/10 on our Quality of Company framework, indicating mixed operational fundamentals. At the current price of $2.63, our multi-model valuation analyzes whether the market has already discounted these weaknesses.

The short answer: 7 of 11 CirclFi valuation models project upside for Agape ATP Corporation (ATPC) at $2.63 — the model consensus leans bullish, with a Quality Score of 4.6/10 and Value-Trap risk of 62/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 7 of 11 models see upside — majority bullish
  • Quality Score: 4.6/10 — Weak — below-average fundamentals
  • Value Trap Risk: 62/100 — High danger — likely trap
  • Fair Value Range: $0.21 – $10.31 (4910% spread)

Bullish Models

7 / 11

Bearish Models

4 / 11

Quality Score

4.6 /10

Weak — below-average fundamentals

Value Trap Risk

62 /100
High danger

High danger — likely trap

Model Consensus

11 /13
Active Models

Avg. confidence: 23%

Investment Thesis

The Bull Case

Target: $10.31 (+292.1% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $2.63 and the composite fair value of $3.97 implies +51.1% upside potential.
  • According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model targets a fair value of $10.31 (+292.1%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.21 (-92.2%)

  • According to the CirclFi Quality of Company (QOC) framework, Agape ATP Corporation's score of 4.6/10 signals fundamental weaknesses that could undermine the investment thesis.
  • According to the CirclFi Value Trap detector, Agape ATP Corporation is flagged with elevated risk (Value Trap score of 62/100), suggesting that apparent cheapness may mask fundamental decay.
  • According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $0.21 (-92.2%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +384.3% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

PNTG The Pennant Group, I
9.3
PRVA Privia Health Group,
8.3
USPH U.S. Physical Therap
8.0
LFST LifeStance Health Gr
6.7
INNV InnovAge Holding Cor
6.7

Valuation Divergence

Spread

4910%

Fair Value Range

$0.21 – $10.31

A 4910% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

EROIC

$10.31 (+292.1%)

Most Bearish

EPV

$0.21 (-92.2%)

Key Risk Factors

Weak Fundamentals

QOC 4.6/10 signals below-average quality.

Value Trap Warning

VT score 62/100 — apparent discount may mask decay.

Model Disagreement

4910% spread signals high variance in projections.

Macro/Sector Risk

Services-Health Services headwinds could affect earnings trajectory.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ATPC Data Page →

The Bottom Line

Agape ATP Corporation leans positive in our analysis — 7/11 models bullish, composite fair value of $3.97 vs. $2.63, QOC 4.6/10. The case is constructive but not overwhelming, and the 4 dissenting models shouldn't be dismissed. Position sizing should reflect this moderate conviction level.

These are quantitative model outputs, not investment recommendations. Agape ATP Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ATPC stock right now?

Based on CirclFi's multi-model analysis, 7 of 11 models see upside for ATPC at $2.63. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 4.6/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Agape ATP Corporation?

Key risks include: an elevated Value Trap score of 62/100, suggesting apparent undervaluation may mask deteriorating fundamentals; a below-average Quality Score of 4.6/10, indicating fundamental weakness; wide model disagreement (4910% spread), signaling high uncertainty; general market and sector-specific risks affecting Services-Health Services companies. Always diversify and consult a financial advisor.

How does ATPC compare to its competitors?

Among Services-Health Services peers, ATPC holds a Quality Score of 4.6/10. Comparable companies include PNTG (QOC 9.3), PRVA (QOC 8.3), USPH (QOC 8.0). The relative ranking helps investors identify whether ATPC offers better fundamental quality than alternatives in the same sector.

Is ATPC a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATPC's Quality Score of 4.6/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy ATPC at?

CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $0.21 to $10.31. At $2.63, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ATPC.

View ATPC Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →